07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

Reolysin: Additional Phase II data

Additional data from the open-label, U.S. Phase II REO 017 trial in 33 chemotherapy-naive patients with advanced or metastatic pancreatic cancer showed that first-line treatment with IV Reolysin plus gemcitabine led to a median overall...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

Reolysin regulatory update

The European Commission granted Orphan Drug designation to Reolysin from Oncolytics to treat ovarian, fallopian tube and primary peritoneal cancers. The formulation of human reovirus type 3 is in Phase III testing to treat platinum-refractory...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Clinical News

Reolysin: Completed Phase II enrollment

Oncolytics Biotech said the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) completed enrollment of 103 patients in an open-label, Canadian Phase II trial comparing IV Reolysin plus FOLFOX-6 and Avastin bevacizumab vs. FOLFOX-6...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

Reolysin: Completed Phase II enrollment

Oncolytics said the Gynecologic Oncology Group (GOG) completed enrollment of about 150 patients in an open-label, U.S. Phase II trial comparing IV Reolysin on days 1-5 of 28-day cycles plus paclitaxel on days 1, 8...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

Reolysin: Completed Phase II enrollment

Oncolytics said NIH’s NCI completed enrollment of 70 patients in the open-label, U.S. Phase II OSU-10045 trial comparing carboplatin and paclitaxel on day 1 plus IV Reolysin on days 1-5 of 21-day cycles vs. carboplatin...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

Reolysin: Preliminary Phase I data

Preliminary data from the single-arm, open-label, dose-escalation, U.S. Phase I REO 022 trial in 18 evaluable patients with oxaliplatin-refractory mutant KRAS mCRC showed that IV Reolysin on days 1-5 of a 28-day cycle plus FOLFIRI...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Clinical News

Reolysin: Additional Phase III data

Data from the subgroup of 118 patients with loco-regional head and neck cancer with or without distal metastases in the double-blind, international Phase III REO 018 trial showed that IV Reolysin plus carboplatin and paclitaxel...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Reolysin: Additional Phase II data

Additional data from the open-label, U.S. Phase II REO 016 trial in 36 evaluable patients with metastatic or recurrent K-Ras or EGFR-activated stage IV NSCLC showed that Reolysin plus paclitaxel and carboplatin led to an...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Reolysin: Updated Phase II data

Oncolytics reported updated data from 25 evaluable chemotherapy-naïve patients with stage IIIB or IV metastatic or recurrent SCC of the lung in the 2-stage, open-label, U.S. Phase II REO 021 trial showing that IV Reolysin...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Clinical News

Reolysin: Preliminary Phase II data

Preliminary data from 14 patients with metastatic melanoma in the first stage of the 2-stage, single-arm, open-label, U.S. Phase II REO 020 trial showed that IV Reolysin plus paclitaxel and carboplatin led to 3 partial...